LiveWell Canada Inc. (“LiveWell” or the “Company”) (CSE:LVWL) is pleased to announce that LiveWell has signed a binding letter of agreement to acquire 100% of Vitality CBD Natural Health Products Inc. and its wholly-owned U.S. subsidiaries (“Vitality”), which will result in a reverse takeover transaction by Vitality (the”Transaction”).

The Transaction will enable the combined companies to become a new leader in the health and wellness market for CBD products from hemp and cannabis. Vitality, a cultivator and producer of hemp CBD, and LiveWell, a cannabidiol (“CBD”)researcher, developer, marketer and distributor, will combine their U.S. and Canadian operations to address the anticipated growing demand for CBD and other cannabinoid products in North American and international markets.

The Transaction will bring together strategically aligned U.S. and Canadian assets to create one of the first fully integrated CBD companies: one of the largest hemp cultivation and CBD extraction operations in North America, which is anticipated to be producing 3,000 kilograms per day of CBD isolate by mid-2019; CBD research, product development and GMP manufacturing facilities; international sales networks; and experienced leadership. The new Canadian company (“Merger Co”) will be headquartered in Ottawa, Ontario, with locations in Las Cruces, New Mexico, and Eureka, Montana, United States, in addition to Gatineau, Quebec, Canada.

Legalization and acceptance of CBD products for health and wellness is accelerating globally.  CBD is most commonly used to treat anxiety, insomnia, pain and nausea, but is being investigated as a treatment for other conditions. Earlier this year, the U.S. FDA approved the CBD drug, Epidiolex, for treatment of childhood epilepsy. The World Health Organization has recommended that CBD be descheduled across its 194 nation members.

The market for hemp CBD products is rapidly emerging and is expected to eclipse recreational cannabis. CBD and other cannabinoids can be extracted from both hemp and cannabis, but hemp faces fewer legal restrictions worldwide and is more economical to cultivate than cannabis. The Brightfield Group of Chicago has estimated that the North American market alone for CBD from hemp could reach US$22 billion by 2022.

On Nov. 29, 2018, the U.S. Senate and House Agriculture Committee Chairmen jointly announced an agreement in principle that would legalize hemp under the U.S. 2018 Farm Bill. The anticipated passage of the final Farm Bill is expected to dramatically impact the demand for hemp products in the United States — and possibly beyond, therefore potentially positioning the Merger Co to capitalize on this opportunity. Although hemp cultivation, processing and sales are currently legal in the U.S. under the Agricultural Act of 2014 if conducted pursuant to a state Department of Agricultural pilot program, the passage of the 2018 Farm Bill would essentially grant industrial hemp the same unrestricted legal status federally as any other agricultural commodity.

Being able to address the full spectrum of this emerging market, from large-scale cultivation to safe and effective consumer outcomes, makes the Merger Co unique among its peers. “This transaction is about meeting and satisfying patient and consumer needs. We are transforming to a global life sciences company, leveraging a robust supply chain and production capacity, while focusing on a differentiated brand development strategy that prioritizes innovative and functional products and outcomes,” said David Rendimonti, President and CEO of LiveWell.

“While North American markets are the primary focus for wholesale and consumer sales initially, European and South American markets are also on the horizon for the Merger Co.,” Mr. Rendimonti said.

“As the cannabis and hemp industry grows and matures, we believe the combined organization better positions us for large-contract opportunities, greater market awareness and long-term success,” said Robert Leaker, President and CEO of Vitality. He further added: “We’ll have the resources to rapidly scale to meet the anticipated explosive demand in newly legalized CBD markets worldwide, we’ll have broader management experience, and we already share a vision of excellence backed by research and science.”

The two companies have a history of strategic joint ventures.  As previously announced on October 30, 2018, Vitality and LiveWell signed a binding term sheet on October 27, 2018, for a major CBD supply and marketing deal with Global Wellness Distributors LLC., a company controlled by a U.S. private equity firm (“CBD Transaction”). The CBD Transaction, anticipated to be finalized by December 31, 2018, is for 1,000 kg/month commencing in January 2019, increasing to 3,000 kg/month in April 2019.


  • 20,000 acres of CBD hemp harvested in 2018.
  • Two extraction facilities with capacity to produce an estimated 100 kg/day of CBD isolate starting in December 2018, increasing to 3,000 kg/day by the second half of 2019.
  • Footprint in Canada and the United States.
  • Personalized diagnostics and patented therapeutics R&D capabilities.
  • 36,000-square-foot nutraceuticals development and manufacturing facility, including 20 pharmaceutical-grade clean rooms. Located close to Canada/U.S. border near Windsor, Ontario, the facility is certified by Health Canada, is FDA registered and has NSF certifications for GMP, for Sport, and is USDA-Certified Organic.
  • Team of researchers and scientists specializing in CBD and other cannabinoids. Have completed a seven-month study and major market report on CBD, as well as a white paper on CBD from Industrial Hemp.
  • 540,000-square-foot greenhouse facility on 100 acres of land with 61,000 square feet completed for cannabis production (20,000 sq. ft. grow space and 41,000 sq. ft. support space).
  • LiveWell’s current market capitalization is floating at approximately $110-$120 million, which will represent 15% of the Merger Co.

As noted below under “Financial Terms of the Transaction”, this Transaction will result in a reverse takeover of LiveWell by Vitality.  Accordingly, this constitutes a fundamental change under CSE Policy 8 and therefore the Transaction and successful listing of the new Merger Co will be subject to CSE approval (see below “Transaction Conditions”).

About Vitality CBD Natural Health Products Inc.
Vitality is a privately-owned Canadian company and one of North America’s largest cultivators and producers of bulk CBD isolates from hemp. Vitality’s hemp cultivation, processing and sale activities are fully certified and compliant under U.S. state and federal laws, as per the Montana Farm Act.  It also has cultivation operations in Alberta. In 2018, Vitality planted and harvested 20,000 acres of industrial hemp, purposely planted for CBD production (19,000 in Montana across 33 farms and 1,000 acres at one farm in Alberta).

Vitality is currently producing CBD isolate in its facility at Eureka, Montana, with existing capacity to reach 100 kg/day of CBD isolate in December 2018.  Vitality also acquired additional production capacity in Las Cruces, New Mexico, where it plans to retrofit the existing production/extraction equipment. By the second half of 2019, Vitality’s total production capacity of CBD products, at both plants, is anticipated to reach more than 3,000 kg/ day. Vitality management anticipates a capital investment of up to US$10 million for the New Mexico location, to be funded by future capital raise. The products offered include CBD isolate, CBD distillate and CBD full-spectrum soft gels.

About LiveWell Canada Inc.
LiveWell is an innovative Canadian hemp and cannabis company focused on advanced research on CBD and other cannabinoids, as well as developing, marketing and distributing consumer health and wellness products.  The company is a late-stage cannabis cultivation applicant with two locations: Ottawa, Ontario, and Litchfield, Quebec.   A Research and Innovation Centre is also planned for the site in Litchfield to further LiveWell’s discovery in CBD and other cannabinoids.

LiveWell’s team of researchers and scientists recently completed a seven-month study and major market report on CBD, has published a white paper on CBD from Industrial Hemp, is working on CBD product formulations and partnering with other research entities. LiveWell has leadership experience from the pharmaceutical, engineering, consumer marketing, food and grocery industries, and the ability to leverage commercial and strategic expertise in global markets.

In October 2018, LiveWell announced it was acquiring Acenzia Inc., a Windsor, Ont.-based developer and manufacturer of nutraceutical products for the health and wellness market. Acenzia specializes in patented therapeutics specific to particular medical conditions and personalized diagnostics. It also offers a manufacturing facility that is certified by Health Canada, is FDA registered and has NSF certifications for GMP, for Sport, and is USDA-Certified Organic.  The acquisition is expected to close by the end of 2018.

At the closing of the Transaction, LiveWell will issue sufficient number of common shares to shareholders of Vitality in order for Vitality shareholders to own 85% of the total fully diluted outstanding and issued common shares of LiveWell. Furthermore, Vitality shareholders are entitled to receive an additional 5% of the total fully diluted outstanding and issued common shares of LiveWell if Vitality achieves the performance milestone, as defined in the binding letter of agreement, by June 30, 2019. The Transaction will constitute a reverse takeover of LiveWell (see below for appointment of Directors and Officers).  Because the Merger Co intends to list on one of the major stock exchanges in the United States shortly after the closing of the Transaction, the parties may consider a share consolidation at the closing of the Transaction, which will be determined at the time of the definitive agreement.

The following includes pertinent, relevant unaudited financial information of Vitality at October 31, 2018, as prepared by Vitality management:

  • Current assets were approximately US$400 million, virtually all related to the estimated carrying value of inventory (harvested hemp biomass) on 20,000 acres based on observable market transactions excluding volume discount.
  • Total liabilities were approximately US$30 million, including US$0.7 million customer deposits.

For the ten months ended October 31, 2018, Vitality had not generated significant revenue (approximately US$1 million) due to its start-up phase and new extraction facility that becomes fully operational in December 2018.   Its operating expenses for the same period were approximately US$2 million.

Audited consolidated financial statements of Vitality for the period from August 1, 2017, to September 30, 2018, will be provided to LiveWell shareholders to approve the Transaction (see below Transaction Conditions).

When the Transaction closes, the following directors and key executive officers will be appointed to lead the Merger Co:

Mike Mueller, Chairman of the Board
Mr. Mueller was President and CEO of MDS Capital Corp. from 2003 to 2005. Prior to that, he held a number of senior positions at TD Bank Financial Group, including Senior VP and Country Head of its USA Division, and Vice Chairman and Head of Global Investment Banking. Mr. Mueller has served on a number of corporate and non-profit boards, including as Chairman of PSP Investments. He is currently Chairman of Revera Inc., a privately held company in the seniors living space, with more than 50,000 residents worldwide.

Bill MacKinnon, Audit Committee Chairman
Mr. MacKinnon is a Chartered Professional Accountant. He was the CEO of KPMG from April 1999, until his retirement in December 2008. Post-retirement he has served on a number of corporate and non-for-profit boards, including Telus Corporation and The Public Sector Investment Board. He presently serves on the Audit Committee of both these organizations.

Owen Kenney, Director
The CEO of VitalPure Nutraceutical and co-founder of Vitality, Mr. Kenney has more than 20 years of experience in residential, agricultural, commercial and civil construction and operations, overseeing negotiations with municipalities, landowners, engineers, lawyers and other professionals.

Kent Hoggan, Director
Mr. Hoggan has more than four decades of experience in the United States as a real estate developer specializing in infrastructure and other projects involving zoning, government entitlements and clearance.

David Rendimonti, Director and Chief Executive Officer
Mr. Rendimonti has a 30-year track record in building and leading top brands in the life sciences sector through senior roles at some of the world’s most prominent healthcare organizations, such as Johnson & Johnson and Wyeth Pharmaceuticals (a Pfizer company).

Robert Leaker, President and Chief Operating Officer
Mr. Leaker has more than two decades of leadership experience and a track record of creating and commercializing new business ventures, leveraging his unique background in science, engineering and business finance.

Steven Archambault, Chief Financial Officer and Chief Administrative Officer
Mr. Archambault is an accomplished finance executive with more than 20 years of experience with private and public companies, including companies listed on the NYSE and TSE senior exchanges.

The Board will also appoint two additional independent directors from the life sciences sector during the first half of 2019.


In light of the conflict of interests from certain executives and directors due to equity ownership in both LiveWell and Vitality, the Chairman of LiveWell also serving as a director of Vitality, and LiveWell’s Chief Innovation and Science Officer also serving as the President and CEO of Vitality, the Board of Directors of LiveWell created an Independent Committee to review and preliminary approve the binding letter of agreement.  The Independent Committee retained the services of Haywood Securities Inc. to obtain a fairness opinion on the Transaction and retained Lawson Lundell as legal advisors.

Given the conflict of interests described above, the Board of Directors of Vitality also created an Independent Committee to review and approve the binding letter of agreement.  Vitality and the Independent Committee utilized Durham Jones & Pinegar, P.C. and the Law Office of David W. Steffensen, P.C. as U.S. legal advisors and will also retain a Canadian legal advisor.


The Transaction is subject to the following key deliverables: execution of definitive agreement, following satisfactory due diligence by both LiveWell and Vitality; completion of the audited consolidated financial statements for Vitality; completion of the fairness opinion by Haywood Securities Inc.; final approval by LiveWell’s Independent Committee; completion and consummation of the acquisition of Acenzia Inc. by LiveWell; completion and consummation of the acquisition of all of the assets (free and clear of all liens and encumbrances) of Vitalpure LLC by Vitality; approval by LiveWell’s shareholders at a Special Meeting to be scheduled; receipt of regulatory approval; and other customary closing conditions.

The Transaction is expected to close by March 31, 2019.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements about LiveWell and its business. Often, but not always, forward-looking statements can be identified by the use of words such as “plan”, “continue”, “expect”, “schedule”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements (including negative variations) that certain events or conditions “may” or “will” occur.

These forward-looking statements include, but are not limited to, statements regarding benefits and timing of the proposed Transaction, the completion of the CBD Transaction, the completion of LiveWell’s acquisition of Acenzia Inc., the completion of Vitality’s acquisition of Vitalpure LLC, the hemp production capacities of Vitality, the estimated value of Vitality’s assets and liabilities, and the market demand and growth with respect to CBD and other cannabinoid products.  There are a number of risks and uncertainties associated that could cause actual results to differ materially from the forward-looking statements included in this communication. For example, the expected timing and likelihood of completion of the pending Transaction, including the due diligence and the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the pending Transaction that could reduce anticipated benefits or cause the parties to abandon the transaction, the ability to successfully integrate the businesses, the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction agreement, the possibility that LiveWell shareholders may not approve the Transaction, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed Transaction, and the risk that any announcements relating to the proposed Transaction could have adverse effects on the market price of LiveWell’s common stock. All such factors are difficult to predict and are beyond our control.

Furthermore, the forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of unknown and known risk factors and uncertainties affecting LiveWell and Vitality. Accordingly, LiveWell cautions that this foregoing list of material factors is not exhaustive, and readers are encouraged to read all Risk Factors disclosed in the Company’s Management Discussion & Analysis datedOctober 26, 2018.

The forward-looking information contained in this press release represents expectations of LiveWell as of the date of this press release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While LiveWell may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For more information, visit

SOURCE LiveWell Canada Inc. 

For further information: Media, English – Deborah Stokes, 819 576-3789 –; French – Dorra Jemail, 819 718-2042 (8:30 am-4:30 pm),; Investors, Nicole Marchand – 416 428-3533 –; Company, David Rendimonti, President and CEO – 819 718-2042 —; Steven Archambault, Chief Financial Officer – 819 718-2042 –


Multi-state cannabis leader highlights events, partnerships, and activities to coincide with Juneteenth holiday

Trulieve Cannabis Corp . (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States and its dispensary group Solevo Wellness, today announced the sponsorship of expungement clinics in Pittsburgh, Pennsylvania as well as additional initiatives celebrating the Juneteenth holiday.

Keep reading... Show less

A summertime series of expungement events, employee volunteerism, documentary filmmaking, fundraising and more demonstrate the importance of commitment to reform and restorative justice to build an equitable, inclusive cannabis industry

Today, on the 50 th anniversary of when America started its longest war—the War on Drugs— Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced the launch of a summer-long social justice campaign supported by its Sunnyside retail brand and flagship cannabis brand, Cresco . Through community expungement events, employee volunteerism, a film documenting the impact of unjust prosecution, and financial contributions from the Company and our third-party vendors, the “Summer of Social Justice” campaign aims to influence reform to help shape a future cannabis industry with limitless opportunities for everyone. The campaign will amplify the ongoing restorative justice, community business incubator and education and workforce development programming facilitated by the Company’s established SEED (Social Equity & Education Development) initiative.

Keep reading... Show less

Florida’s legal cannabis program has gained plenty of investor attention as the potential for this segment of the US cannabis market continues to expand.

The US cannabis industry is largely fragmented because the plant remains illegal at the federal level. Despite that obstacle, several states across the country have implemented medical and recreational cannabis legislation allowing for cultivation, processing, commercial sale and consumer use.

While this legislation differs greatly from state to state, one state’s medical cannabis industry has seen unprecedented growth: Florida.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

The coastal state’s journey to cannabis legalization has been a challenging one. In 2016, over 70 percent of Floridians voted for a constitutional amendment to allow the use of cannabis for medical purposes.

However, in the 2017 legislation that created the state’s legal medical cannabis framework, then-Governor Rick Scott banned smoking medical cannabis. It wasn’t until March 2019 that Ron DeSantis, the current governor of Florida, lifted the ban on smokable marijuana.

In the face of those challenges, the Sunshine State has developed one of the most attractive medical cannabis markets in the country. In fact, Florida’s medical marijuana space is one of the fastest growing in the country.

Read on to learn more about the investing opportunities in Florida’s legal cannabis space and the top marijuana stocks to look out for.

Florida medical cannabis: High-growth market

Florida’s large population — the third biggest in the US — is a factor in the attractiveness of its cannabis market. The state is also the fourth largest economy in the US with a gross domestic product of just over US$1 billion in 2020.

A 2020 report from Arcview Market Research and BDS Analytics shows the US legal cannabis industry is expected to grow by 18.2 percent between 2019 and 2025 to reach US$33.9 billion. Florida ranks among the jurisdictions that will contribute the most to that growth.

“The Total Available Market, or TAM, is one of the most critical factors for any industry,” states Dustin Robinson, founding partner of Mr. Cannabis Law, in an article written for Green Entrepreneur. “Florida’s marijuana industry happens to have one of the strongest TAMs in the world.”

As of a June 2021 update from Florida Health’s Office of Medical Marijuana Use (OMMU), the state had 569,450 qualified medical marijuana patients and 2,542 qualified physicians.

Florida’s patient count is a small percentage of its population of 21 million, but it has been steadily growing since the drug was legalized in the state in 2016. In fact, the patient figure has more than doubled in the past two years.

According to Robinson, there are almost 300 retail locations in Florida, with another 500 locations expected by the end of 2022.

Beacon Securities analyst Russell Stanley has said Florida boasts a healthy list of addressable medical conditions that can be treated with cannabis, unlike the medical marijuana programs in other states.

“Some other states have had trouble expanding their programs, in part because it’s been very difficult for patients to get access to product,” Stanley told the Investing News Network. “Other states have had restrictions on which healthcare practitioners can recommend it and what they can recommend it for.”


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Florida cannabis market: High barriers to entry

The 2017 Florida medical marijuana law established a cap on the number of medical marijuana dispensaries and required that each center be vertically integrated — they all had to manage their own operations, from cannabis cultivation and processing to distribution and sales.

The cap on the number of dispensaries expired in April 2020. While the vertical integration requirement portion of the law underwent a three year court battle, the Supreme Court of Florida recently upheld the legislation, meaning this requirement will continue to shape the Florida cannabis market for years to come.

During a panel discussion, Steve Hawkins, CEO of Horizons ETFs Management (Canada), said he views vertical integration as one of the key benefits for US companies compared to the Canadian cannabis market. Only players that have been able to develop cannabis production, manufacturing and distribution capabilities can compete in the marketplace.

As of March 2021, the state had 22 licensed medical marijuana treatment centers (MMTCs) and five laboratories licensed for third party testing. The low number of licenses currently awarded creates high entry barriers, which is a big plus for the currently operating companies that have already established a strong foothold in the market.

Robinson believes that “the 22 Licensees are in a great position to build multi-billion-dollar companies in Florida’s growing marijuana industry.”

These 22 established licensees will also have an advantage if and when recreational cannabis becomes legal in the state. “In Florida, the medical marijuana license allows the current MMTCs to build out as big of a footprint as possible in preparation for adult use (recreational) legalization,” he said.

Florida cannabis market: Top Florida cannabis stocks

As the legal cannabis industry grows in Florida, some players have begun to stand out in the state.

Florida native Trulieve Cannabis (CSE:TRUL,OTC Pink:TCNNF) holds the lion’s share of the market and has continually been a top-performing stock in the state.

Trulieve opened Florida’s first medical marijuana dispensary back in 2016, and since then it’s grown into a force in the industry, with a current market capitalization of US$5.52 billion.

As of June 4, 2021, Trulieve had 82 dispensing locations in the state, according to data released by the OMMU. In one week’s time it sold more than 76.5 million milligrams of tetrahydrocannabinol (THC) products and 1.6 million milligrams of cannabidiol (CBD) products, in addition to 32,295 ounces of dried flower.

Shortly after smokable marijuana was legalized, Trulieve began selling flower and was the first in the state to do so. Trulieve has also benefited from a vertically integrated structure that includes cannabis cultivation, production and distribution, which is essential since cannabis cannot be moved across states lines just yet.

Surterra Wellness comes in at a distant second place with 39 dispensing locations and sales of over 22.2 million milligrams of THC products and 1.6 million milligrams of CBD products, in addition to 6,911 ounces of dried flower. Surterra is owned by Parallel, one of the largest privately held multi-state cannabis operators (MSOs) in the country.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Parallel recently announced its intentions to go public through a definitive business combination agreement with Ceres Acquisition (NEO:CERE,OTCQX:CERAF), a special purpose acquisition company.

Another big player in the state is Massachusetts-based Curaleaf Holdings (CSE:CURA,OTCQX:CURLF). Though not native to Florida, Curaleaf’s presence in the state’s cannabis business is substantial. Of the MSO’s total 101 dispensaries, 37 are in Florida, putting it in third place behind Trulieve and Surterra.

The vertically integrated company also launched the state’s first medical cannabis tablets in September 2019, followed by the first sublingual tablets in July 2020.

Curaleaf put up impressive revenue numbers for 2020, reporting retail revenue of US$423.2 million compared to US$138.7 million in 2019. The company attributed the 205 percent increase to new store openings in its operating states, including five opened in Florida in 2020.

Liberty Health Sciences, which was acquired by Ayr Wellness (CSE:AYR.A,OTCQX:AYRWF) in February 2021 in all-stock transaction, also has a considerable stake in Florida. According to the OMMU, Liberty currently has 36 dispensing locations in the state.

Ayr Wellness plans to increase that footprint to 42 dispensaries by the end of 2021, and has a target of roughly US$4 million in annual retail revenues per store for 2022. In May 2021, the company announced the launch of its Origyn premium concentrate line in the state. The product line includes wax, crumble, Rick Simpson oil and shatter. Ayr has also begun construction of a 10 acre outdoor cultivation expected to be completed in Q3 2021.

Florida cannabis market: Investor takeaway

As its medical marijuana industry continues to grow, Florida has a lot to offer in terms of investment opportunities. BDS Analytics projects that Florida’s medical cannabis market will hit US$1.5 billion in sales in 2021, up 53 percent over 2020 sales.

The research firms predicts that recreational cannabis could be legal by 2023, which would set Florida on a path to become the third largest US legal cannabis market by 2026. Regardless of whether adult use gets the green light that soon, investors should still consider the Sunshine State as a premier cannabis jurisdiction.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 90th nationwide.

The latest dispensary, located in the Florida Keys, supports Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The Tavernier dispensary joins the nearby Key West dispensary, as well as several others throughout the Miami area.

Keep reading... Show less

Company to Donate: $30,000 to Assist with Elk Grove Village’s Community Events and Outreach Programs; Additional $15,000 to Go Towards Supporting Alexian Brothers Medical Center’s Foundation, Elk Grove Village Police Drug Education Program and Kenneth Young Youth Center

Keep reading... Show less